Library
of Slides and Posters
Therapy
for Treatment-naïve Patients
Therapy for Treatment-experienced Patients
Lipodystrophy and Metabolic Changes
HIV-related Adverse Events
Pharmacokinetic Interactions
 Therapy
for Treatment-naïve Patients
A Randomized Comparative Trial
of First-line Antiretroviral Therapy with Regimens Containing Either Nevirapine,
or Efavirenz, Together with Stavudine and Lamivudine. Three-Year Extended Follow-Up
of the 2NN Study.
F Wit and others.
Predicting
Response to Therapy for HIV-1 Infection in ART-naïve Adults Starting HAART Regimens
by Using the Week 8 Time-point
L
Yau and others. Copyright GlaxoSmithKline. Used with permission, 2007.
An
Open-Label, Two-Period, Crossover, PK Study of Abacavir (ABC) and Its Intracellular
Anabolite Carbovir Triphosphate (CBV-TP) Following 600mg Once-Daily and 300mg
Twice-Daily Administration of Abacavir in HIV-Infected Subjects
G
Moyle and others. Copyright GlaxoSmithKline. Used with permission, 2007.
Once-Daily
Ritonavir (100mg) Boosting of Fosamprenavir (FPV/r) or Atazanavir (ATZ/r) with
Tenofovir (TDF)/Emtricitabine (FTC) in Antiretroviral-Naive HIV-Infected Patients:
48-week Safety/Efficacy Results from COL103952 (ALERT)
K
Smith and others. Copyright GlaxoSmithKline. Used with permission, 2007.
Long-Term
Efficacy and Safety of Fosamprenavir (FPV) 1400 mg Once-Daily (QD) Boosted by
Ritonavir (RTV) 100 mg QD in Previously Antiretroviral-Naïve HIV/AIDS Patients:
Phase I of BOLD100 (COL109766)
G
Blick and others. Copyright GlaxoSmithKline. Used with permission, 2007.
Virologic
Response and Tolerability by Sex and Race in Subjects Receiving Fosamprenavir/ritonavir
(FPV/r) BID and Lopinavir/ritonavir (LPV/r) BID, each in Combination with Abacavir/Lamivudine
QD (the KLEAN Study)
E
DeJesus and others. Copyright GlaxoSmithKline. Used with permission, 2007.
Once-Daily
Abacavir/Lamivudine (ABC/3TC) and Boosted Atazanavir (ATV/r): 48-Week Analysis
from COL102060 (SHARE)
R
Elion and others. Copyright GlaxoSmithKline. Used with permission, 2007.
LPV/r-based
2-drug HAART vs LPV/r-based 3-drug HAART: Comparable Virological Efficacy and
Tolerability in HIV-1-infected Naïve Subjects (Kalead-1 study) 48-week Results
M
Pinola, G Carosi, G Di Perri, and others
Single-agent
Therapy with Lopinavir/ritonavir Suppresses Plasma HIV-1 Viral Replication in
HIV-naïve Subjects: IMANI-2 48-week Results
J C Gathe Jr, R F
Yeh, C Mayberry, and others
Saquinavir/r
(SQV/r) BID vs lopinavir/r
(LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD
as initial therapy in HIV-1 infected patients: the Gemini Study.
F Raffi, D Ward, K Ruxrungtham, and others
Therapy
for Treatment-experienced Patients
Week
8 response predicts Week 48 virological responses to tipranavir/r in the RESIST
studies
J Ernst and others.
Soluble
Immune Markers in Individuals Treated for 6 Years with a Lopinavir/ritonavir (LPV/./r)-based
Antiretroviral (ARV) Regimen
A Landay, M King, J Tschampa, and others
Lipodystrophy
and Metabolic Changes
Nevirapine
Increases High Density Lipoprotein-cholesterol by Stimulation of Apolipoprotein
A-I Synthesis
R Sankatsing and others.
Determination
of Body Composition Changes by Total Body Dual-Energy X-ray Absorptiometry after
48 Weeks of Treatment with Once-Daily Fosamprenavir (FPV) Boosted with Two Different
Doses of Ritonavir(r) plus Abacavir(ABC)/Lamivudine(3TC): COL100758
D
Wohl and others. Copyright GlaxoSmithKline. Used with permission, 2007.
Once-Daily
Abacavir/Lamivudine (ABC/3TC) and Boosted Atazanavir (ATV/r): 48-Week Analysis
from COL102060 (SHARE)
R
Elion and others. Copyright GlaxoSmithKline. Used with permission, 2007.
One-year
Fat Tissue Distribution Changes in Antiretroviral Naïve HIV-infected Patients
Treated with Lopinavir/ritonavir (LPV/r) Monotherapy versus LPV/r with Zidovudine/lamivudine
(AZT/3TC) in the MONARK Trial
J F Delfraissy, P Flandre, P Van Ngo
Van, and others
Changes
in Lipid Parameters During Treatment with Lopinavir/ritonavir (LPV/r) Plus Zidovudine/lamivudine
(ZDV/3TC) Induction Followed by Maintenance on LPV/r Monotherapy Compared to Efavirenz
(EFV) + ZDV/3TC through 96 Weeks
B da Silva, P Domingo, V Joly V, and
others
Eztimbe Combined
with Low Dose Statin Effectively Lowers LDL in Protease Inhibitor Treated Patients
O
Klibanov, JGaughan, E Tedaldi, and others
Evaluation
of the impact of highly active antiretroviral therapy (HAART) on lipid profiles
– data from the 24-week interim analysis of the Gemini Study: saquinavir/r
(SQV/r) BID vs lopinavir/r
(LPV/r) BID plus emtricitabine/tenofovir (FTC/TDF) QD
in ARV-naïve HIV-1-infected patients.
S
Walmsley, U Bredeek, A Avihingsanon, and others
HIV-related
Adverse Events
No
Change in Glucose Tolerance with Lopinavir/ritonavir (LPV/r) + ZDV/3TC Induction
Followed by LPV/r Monotherapy through 96 Weeks
B da Silva, M King,
M Dehaan, and others
Pharmacokinetic
Interactions
Efficacy
and Safety of Fosamprenavir/ritonavir (FPV/r) BID or Lopinavir/ritonavir (LPV/r)
BID in Antiretroviral Treatment-Naïve Subjects Co-Infected with Hepatitis B (HBV)
or C (HCV) and HIV (the KLEAN Study)
D
Norris and others. Copyright GlaxoSmithKline. Used with permission, 2007.
|
